Zacks: Check Cap Ltd (CHEK) Receives Average Rating of “Strong Buy” from Brokerages

Check Cap Ltd (NASDAQ:CHEK) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 1-year consensus target price of $4.58 for the company and are forecasting that the company will post ($0.14) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Check Cap an industry rank of 174 out of 265 based on the ratings given to its competitors.

A number of research analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target (up from $6.00) on shares of Check Cap in a research report on Thursday, September 28th. Maxim Group reissued a “buy” rating and set a $5.00 target price on shares of Check Cap in a research report on Wednesday, September 27th. Finally, Zacks Investment Research raised shares of Check Cap from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research report on Tuesday, October 3rd.

A hedge fund recently raised its stake in Check Cap stock. Sabby Management LLC lifted its position in shares of Check Cap Ltd (NASDAQ:CHEK) by 467.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,418,893 shares of the medical research company’s stock after purchasing an additional 1,169,061 shares during the period. Check Cap comprises 0.1% of Sabby Management LLC’s portfolio, making the stock its 24th largest position. Sabby Management LLC owned 8.36% of Check Cap worth $2,724,000 at the end of the most recent reporting period. Institutional investors own 18.97% of the company’s stock.

Shares of Check Cap (NASDAQ:CHEK) traded up $0.05 during mid-day trading on Wednesday, reaching $0.98. 3,078,100 shares of the company’s stock were exchanged, compared to its average volume of 252,600. The firm has a market capitalization of $15.74, a PE ratio of -1.60 and a beta of -0.68. Check Cap has a 1 year low of $0.80 and a 1 year high of $2.55.

WARNING: “Zacks: Check Cap Ltd (CHEK) Receives Average Rating of “Strong Buy” from Brokerages” was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at

About Check Cap

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Get a free copy of the Zacks research report on Check Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with's FREE daily email newsletter.

Leave a Reply